Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.42 |
| ▸ | F2RL1 | P55085 | 3/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6849910 | 0.88 | USP30 (0.44) | F2RL1REN | |
| SCHEMBL6850517 | 0.87 | PSEN1 (0.44) | F2RL1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6849973 | 0.86 | REN (0.38) | F2RL1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6850279 | 0.85 | F2RL1 (0.42) | CTSSF2RL1REN | |
| SCHEMBL6850689 | 0.83 | PSEN1 (0.46) | F2RL1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6850092 | 0.83 | LONP1 (0.54) | CTSSF2RL1 | |
| SCHEMBL6845923 | 0.82 | F2RL1 (0.43) | CTSSF2RL1REN | |
| SCHEMBL6848900 | 0.81 | CTSS (0.37) | CTSSF2RL1PSEN1PSEN2APH1B | |
| SCHEMBL6848816 | 0.79 | LONP1 (0.56) | CTSSF2RL1 | |
| SCHEMBL6848769 | 0.74 | LONP1 (0.54) | CTSSF2RL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6774212-B2 | FOR THERAPY OF VIRAL INFECTION OR AS AN ASSAY STANDARD OR REAGENT | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-10 | — | — | US | disclosed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | CES1, CYP51A1, SPINT2 | CTSS 135/4885F2RL1 1971/4885PSEN1 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.